The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
2. Which of the following is associated with this condition? 
1. This antinuclear antibody (ANA) is most characteristic of:
2. Which of the following is associated with this condition?
